RATIONALE: Asthma control determination relies on accurate reporting of SABA utilization; however, it is often limited by recall bias. We therefore assessed the utility of self-reported SABA use. METHODS: Data were collected from 1,062 adults (2016-2018) with self-reported asthma and > _4 weeks of EMM-recorded SABA use prior to the completion of a mobile Asthma Control Test (ACT). ACT Question 4 (Q4) assessed self-reported rescue inhaler/nebulizer medication use during the prior 4 weeks with responses: 1) not at all, 2) < _1x/week; 3) 2-3x/week; 4) 1-2x/day; and 5) > _3x/day. Four-week mean EMM-recorded SABA puffs was binned into comparable responses: 1) 0/week; 2) 1x/week; 3) >1-3x/ week; 4) >3-14x/week; and 5) >14x/week. Asthma was considered ''uncontrolled'' with responses of 3), 4), or 5), then sensitivity, specificity, and area under the receiver operating curve (AUC) was calculated to evaluate the utility of Q4 on EMM-defined ''uncontrolled'' asthma using logistic regression. Lastly, prevalence of under-reported SABA use was quantified as the proportion of patients with a Q4 response coinciding with lower EMM-recorded use. RESULTS: The median Q4 response was 3 (IQR:2-4) and EMMs recorded on average 8 (SD:16) puffs/week. Approximately 60.5% and 64.9% of patients had uncontrolled asthma according to Q4 and EMMs, respectively. The Q4 sensitivity, specificity, and AUC was 82%, 63% and 0.72, respectively, with 35% of patients under-reporting SABA use. CONCLUSIONS: The utility of self-reported vs. objectively-recorded SABA use was good. Under-reporting was prevalent, highlighting the potential value of EMM data to more precisely identify uncontrolled asthma with higher sensitivity.
RATIONALE: Poor patient health literacy and adherence contribute to the high degree of asthma-related morbidity and mortality. We previously developed the patient-facing ASTHMAXcel mobile application, which has been linked to favorable process and clinical outcomes data in adults. We recently created a pediatric version, ASTHMAXcel Adventures. This study evaluates this intervention regarding patient satisfaction and asthma illness representation (IR) among children and caregivers. METHODS: ASTHMAXcel Adventures includes interactive games, animated educational videos, quizzes, and personalized feedback to promote guideline-based asthma management. We enrolled 29 pediatric (7-17 years old) patients into the study. We evaluated pre-intervention IR through the Asthma Illness Representation (AIRS, administered jointly to children and caregivers), then provided participants with the intervention, after which the post-intervention AIRS and the validated Client Satisfaction Questionnaire-8 (CSQ-8 administered to caregivers) were completed. We used Student's t-test to analyze these data. RESULTS: 29 patients (females513) were enrolled into this study, with a mean age of 10.7+/-2.5 years (range 7 to 15 years). Most patients (n522) were highly satisfied (CSQ-8 score greater than 30 of 32 maximum points) with the intervention. Both males and females were equally satisfied with the application (p50.15). Compared to baseline, mean AIRS scores increased after the intervention (31.3+/-9.6 vs 47.4+/-21.7, p<0.01). The change in AIRS was not associated with patient age or gender. CONCLUSIONS: The ASTHMAXcel Adventures mobile application has been linked to improved asthma IRs and a high degree of user satisfaction. Further ongoing studies are evaluating the intervention through a longer time frame and with a larger patient sample. RATIONALE: Chronic cough (CC) is a condition resulting in negative physical, emotional and social outcomes. Objective measures to quantify frequency of cough are necessary in clinical trials to examine treatment efficacy; however, the degree of cough reduction required to be considered a minimal clinically important difference (MCID) has not been defined. The objective was to define the MCID for objective cough counts (OCCs). METHODS: Pooled data from a Phase 2 RCT of an investigational treatment for CC were analyzed. Enrollees were non-smokers, had refractory/unexplained CC for > _1yr, and baseline cough severity VAS > _40mm. The 24-hour OCC (VitaloJAK ä , Vitalograph, Buckingham, UK; Baseline, Week4) and Patient Global Impression of Change (PGIC; Week4) data were analyzed. MCIDs were defined using distribution-based (MCID-D; ½ standard deviation and standard error of measurement) and anchor-based (MCID-A; receiver operating characteristic curves [ROC] and PGIC) analyses. RESULTS: Analyses from n5253 participants (mean age 60.2; 76% female) resulted in MCID-D estimates of 11.3% to 19.7% for OCC. MCID-A/ROC analyses indicated that mean OCC reduction at Week4 of 38% had the best sensitivity/specificity for predicting PGIC responses of ''somewhat improved,'' ''improved,'' or ''very much improved''. Among those reporting themselves as ''somewhat improved'' and ''improved'' vs. ''very much improved,'' the corresponding %reductions in OCC were 29.7% and 57.5%, respectively. CONCLUSIONS: Taken together, these results provide guidance on the degree of change in OCC that can be considered clinically meaningful to help guide treatment decisions and drug development. Specifically, clinicians may consider OCC reductions in the range of 20-30% as the MCID.
